Abstract
Aynı zamanda zona olarak da bilinen herpes zoster, dorsal kök ganglionlarında latent kalan varisella zoster virüsünün reaktivasyonundan kaynaklanmaktadır. Herpes zoster birincil suçiçeği enfeksiyonundan sonra herhangi bir zamanda gelişebilir. Suçiçeği aşısı canlı atenüe bir aşı olduğu için aşıya bağlı herpes zoster de görülebilir. Aktive olmuş virüs kutanöz sinir boyunca yayılarak sinire ait dermatoma uyan ciltte veziküler döküntü ve ağrıya neden olur. Zonada en sık tutulum torasik dermatomda olup, trigeminal sinir ise en sık tutulan kranyal sinirdir. Burada trigeminal sinir tutulumu ile başvuran pediatrik zona olgusu sunulmuştur.
Keywords
References
- 1) Chun C, Weinmann S, Riedlinger K, et al. Laboratory characteristics of suspected herpes zoster in vaccinated children. Pediatr Infect Dis J. 2011;30:719-21.
- 2) Kawai K, Yawn BP. Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2017;92:1806-21.
- 3) Leung AK, Robson WL, Leong AG. Herpes zoster in childhood. J Pediatr Health Care. 2006;20:300-3.
- 4) Dayan RR, Peleg R. Herpes zoster - typical and atypical presentations. Postgrad Med. 2017;129:567-71.
- 5) Feder HM Jr, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23:451-7.
- 6) Hwang JH, Kim KH, Han SB, et al. A clinico-epidemiological multicenter study of herpes zoster in immunocompetent and immunocompromised hospitalized children. Clin Exp Vaccine Res. 2019;8:116-23.
- 7) Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
- 8) Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-53.
- 9) Stein M, Cohen R, Bromberg M, et al. Herpes zoster in a partially vaccinated pediatric population in central Israel. Pediatr Infect Dis J. 2012;31:906-9.
- 10) Staikov I, Neykov N, Marinovic B, et al. Herpes zoster as a systemic disease. Clin Dermatol. 2014;32:424-9.
- 11) Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537-44.
- 12) Kim BS, Mehra S, Yawn B,et al. Increased risk of herpes zoster in children with asthma: a population-based case-control study. J Pediatr. 2013;163:816-21.
- 13) Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28:954-9.
- 14) Saguil A, Kane S, Mercado M, et al. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician. 2017;96:656‐63.
- 15) O'Connor KM, Paauw DS. Herpes zoster. Med Clin North Am. 2013;97:503-22.
- 16) El Hayderi L, Nikkels-Tassoudji N, Nikkels AF. Incidence of and Risk Factors for Cutaneous Scarring after Herpes Zoster. Am J Clin Dermatol. 2018;19:893-97.
- 17) Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013;125:78‐91.
Abstract
Herpes zoster, also known as shingles, appears as a vesicular lesion on the skin as a result of the reactivation of varicella zoster virus, which remains latent in the dorsal root ganglia. Herpes zoster can develop at any time after the primary varicella infection or vaccination. It occurs rarely in healthy children and is mostly self-limiting. An eight-year-old female patient without any underlying immunosuppression history or chronic disease was treated with intravenous acyclovir due to the emergence of new rashes and severe pain while receiving oral acyclovir treatment with the diagnosis of herpes zoster with trigeminal nerve involvement. Oral analgesics and topical lidocaine-containing ointment were applied for pain control. Trimethoprim-sulfamethoxazole treatment was given for bacterial superinfection and intravenous acyclovir treatment was applied for 7 days..
Keywords
References
- 1) Chun C, Weinmann S, Riedlinger K, et al. Laboratory characteristics of suspected herpes zoster in vaccinated children. Pediatr Infect Dis J. 2011;30:719-21.
- 2) Kawai K, Yawn BP. Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2017;92:1806-21.
- 3) Leung AK, Robson WL, Leong AG. Herpes zoster in childhood. J Pediatr Health Care. 2006;20:300-3.
- 4) Dayan RR, Peleg R. Herpes zoster - typical and atypical presentations. Postgrad Med. 2017;129:567-71.
- 5) Feder HM Jr, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23:451-7.
- 6) Hwang JH, Kim KH, Han SB, et al. A clinico-epidemiological multicenter study of herpes zoster in immunocompetent and immunocompromised hospitalized children. Clin Exp Vaccine Res. 2019;8:116-23.
- 7) Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
- 8) Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-53.
- 9) Stein M, Cohen R, Bromberg M, et al. Herpes zoster in a partially vaccinated pediatric population in central Israel. Pediatr Infect Dis J. 2012;31:906-9.
- 10) Staikov I, Neykov N, Marinovic B, et al. Herpes zoster as a systemic disease. Clin Dermatol. 2014;32:424-9.
- 11) Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537-44.
- 12) Kim BS, Mehra S, Yawn B,et al. Increased risk of herpes zoster in children with asthma: a population-based case-control study. J Pediatr. 2013;163:816-21.
- 13) Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28:954-9.
- 14) Saguil A, Kane S, Mercado M, et al. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician. 2017;96:656‐63.
- 15) O'Connor KM, Paauw DS. Herpes zoster. Med Clin North Am. 2013;97:503-22.
- 16) El Hayderi L, Nikkels-Tassoudji N, Nikkels AF. Incidence of and Risk Factors for Cutaneous Scarring after Herpes Zoster. Am J Clin Dermatol. 2018;19:893-97.
- 17) Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013;125:78‐91.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | OLGU SUNUMU |
| Authors | |
| Publication Date | January 14, 2022 |
| Published in Issue | Year 2022 Volume: 44 Issue: 1 |